Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Circulating tumor DNA (ctDNA) are DNA fragments from cancer cells found in bodily fluids.
• Liquid biopsy, commonly using blood or plasma, is a minimally invasive method to obtain ctDNA.
• ctDNA analysis detects mutations, copy-number alterations, gene fusions, and methylation for cancer insights.

Purpose of the Study:

• To review the potential applications of ctDNA in cancer care.
• To highlight the current limited use of ctDNA in gynecologic malignancies compared to other cancers.
• To emphasize the need for further research in ovarian, endometrial, and cervical cancers.

Main Methods:

• Detection of ctDNA using polymerase chain reaction (PCR) or next-generation sequencing (NGS).
• Analysis of ctDNA for various genetic alterations and epigenetic modifications.
• Comparison of ctDNA utility in gynecologic cancers versus other solid tumors.

Main Results:

• ctDNA analysis holds promise for cancer diagnosis, prognosis, targeted therapy, and monitoring treatment response.
• ctDNA provides a less invasive alternative to tissue biopsies, enabling serial monitoring.
• The adoption of ctDNA in gynecologic oncology lags behind other cancer types, with limited dedicated studies.

Conclusions:

• ctDNA has significant potential to improve cancer care through early detection and personalized treatment strategies.
• Further clinical validation and research are crucial to integrate ctDNA into routine management of gynecologic cancers.
• Expanding ctDNA applications in ovarian, endometrial, and cervical cancers could significantly benefit patient outcomes.